Akums Drugs & Pharmaceuticals Ltd. announced the approval of its Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The Board meeting, held on February 13, 2026, adopted the results along with the Limited Review Reports from the Statutory Auditors. Key financial performance data, including revenues and net profit, across both standalone and consolidated formats are detailed for the current quarter and the year-to-date period.
Board Concludes Q3 FY2026 Results Review
The Board of Directors of Akums Drugs & Pharmaceuticals Limited convened on February 13, 2026, to consider and approve the financial outcomes for the period ending December 31, 2025. The meeting formally adopted the Unaudited Standalone and Consolidated Financial Results, which were accompanied by the Limited Review Reports provided by the Statutory Auditors, Walker Chandiok & Co. LLP.
Standalone Financial Highlights (Q3 FY2026 vs. Previous Years)
The standalone results reveal significant year-over-year growth:
- Revenue from Operations (Quarter Ended Dec 31, 2025): ₹3,686.06 million, compared to ₹3,363.92 million in Q3 FY2025.
- Profit Before Tax (Quarter Ended Dec 31, 2025): ₹358.67 million.
- Profit for the Period (Nine Months Ended Dec 31, 2025): ₹1,334.09 million (Consolidated), up from ₹1,334.09 million in the previous year period.
- Standalone EPS (Basic and Diluted): ₹1.84 for the quarter ended December 31, 2025.
Consolidated Performance Overview
On a consolidated basis, the Group’s performance shows:
- Total Income (Quarter Ended Dec 31, 2025): ₹11,939.15 million.
- Profit for the Period Attributable to Owners of the Parent (Q3 FY2026): ₹663.17 million.
- Total Comprehensive Income (Nine Months Ended Dec 31, 2025): ₹1,731.94 million.
Auditor’s Review and Key Notes
The auditors issued a conclusion on the results based on their review, noting that no material misstatement was found. However, two key areas warrant specific attention:
- Income Tax Proceedings: Attention is drawn to a search and seizure operation conducted by the Income Tax Department between January 15, 2025, and January 21, 2025. While the company is responding to subsequent notices for the block period (April 1, 2018, to March 12, 2025), the impact on the current results remains presently not ascertainable.
- New Labour Codes Impact: The Group recognized an incremental charge of ₹182.28 million related to gratuity and compensated absences due to the consolidation of four Labour Codes notified in November 2025. This amount was presented under Exceptional Items.
IPO Proceeds Utilization Update
The company provided an update on the utilization of net IPO proceeds (totaling ₹6,373.70 million). As of December 31, 2025, all planned objects have been fully utilized:
- Repayment of Borrowings (Company & Subsidiaries): Fully utilized at ₹3,869.00 million.
- General Corporate Purposes (GCP): Fully utilized at ₹1,675.00 million, which does not exceed the 25% limit of the fresh issue proceeds.
The company also noted the incorporation of a new subsidiary, Akums Healthcare Malta Private Limited, in October 2025, reflecting a strategic move toward international expansion.
Source: BSE
